Search hospitals > Oklahoma > Lawton
Cancer Centers of Southwest Oklahoma Research
Claim this profileLawton, Oklahoma 73505
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
163 reported clinical trials
25 medical researchers
Summary
Cancer Centers of Southwest Oklahoma Research is a medical facility located in Lawton, Oklahoma. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Cancer Centers of Southwest Oklahoma Research is involved with conducting 163 clinical trials across 318 conditions. There are 25 research doctors associated with this hospital, such as Kathleen Moore, M.D., MS, Raid Aljumaily, Wajeeha Razaq, MD, and Susanna Ulahannan, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Kathleen Moore, M.D., MSUniversity of Oklahoma Health Sciences Center1 year of reported clinical research
Expert in Ovarian Cancer
Studies Endometrial Cancer
32 reported clinical trials
83 drugs studied
Raid AljumailyUniversity of Oklahoma Health Sciences Center8 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
44 drugs studied
Wajeeha Razaq, MDUniversity of Oklahoma Health Sciences Center1 year of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
24 reported clinical trials
46 drugs studied
Susanna Ulahannan, MDUniversity of Oklahoma Health Sciences Center6 years of reported clinical research
Studies Skin Cancer
Studies Colorectal Cancer
24 reported clinical trials
45 drugs studied
Clinical Trials running at Cancer Centers of Southwest Oklahoma Research
Lung Cancer
Breast Cancer
Bladder Cancer
Skin Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Kidney Cancer
Testicular cancer
Squamous Cell Carcinoma
Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Cancer Centers of Southwest Oklahoma Research?
Cancer Centers of Southwest Oklahoma Research is a medical facility located in Lawton, Oklahoma. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Cancer Centers of Southwest Oklahoma Research is involved with conducting 163 clinical trials across 318 conditions. There are 25 research doctors associated with this hospital, such as Kathleen Moore, M.D., MS, Raid Aljumaily, Wajeeha Razaq, MD, and Susanna Ulahannan, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.